Thu, 09 Feb 2023

NEW YORK, NY / ACCESSWIRE / December 6, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Verve Therapeutics, Inc. ('Verve' or the 'Company') (NASDAQ:VERV). Investors who purchased Verve securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/verv.

Bronstein, Gewirtz and Grossman, LLC, Tuesday, December 6, 2022, Press release picture

The investigation concerns whether Verve violated federal securities laws.

On October 31, 2022, Verve issued a press release 'announcing that preclinical data supporting VERVE-101 as a treatment for heterozygous familial hypercholesterolemia (HeFH), a genetic form of atherosclerotic cardiovascular disease (ASCVD), has been published in the American Heart Association's peer-reviewed journal Circulation.' According to the preclinical data reported by the Company, VERVE-101 did not demonstrate significantly greater efficacy than statins, the traditional treatment for patients with high cholesterol. On this news, Verve's stock price fell $3.00 per share, or 7.37%, to close at $37.70 per share on October 31, 2022. Then, on November 7, 2022, Verve announced that 'the U.S. Food and Drug Administration (FDA) has placed a hold on its IND application to conduct a clinical trial evaluating VERVE-101 in patients with heterozygous familial hypercholesterolemia (HeFH) . . . in the United States.' On this news, Verve's stock price fell $9.54 per share, or 30.49%, to close at $21.75 per share on November 7, 2022. Then, on December 5, 2022, Verve disclosed that the FDA had requested additional data to resolve the clinical hold. On this news, Verve's stock price fell $2.58 per share, or 10.75%, to close at $21.42 per share on December 5, 2022.

If you are aware of any facts relating to this investigation or purchased Verve securities, you can assist this investigation by visiting the firm's site: www.bgandg.com/verv. You can also contact Peretz Bronstein or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.

Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits. The firm has recovered hundreds of millions of dollars for investors nationwide. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/730465/Bronstein-Gewirtz-Grossman-LLC-Announces-Verve-Therapeutics-Inc-VERV-Investigation

More Charlotte News

Access More

Sign up for Charlotte News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!